Early Insights on the Real-World Use of Aflibercept 8 mg Among Treatment-Naive Eyes With Diabetic Macular Edema

Nitish Mehta, MD,¹ Steven Sherman, MPH,² Keran Moll, PhD,² Dana Murdock, PhD,² Nick Boucher, BS,³ Rishi P. Singh, MD,⁴ Ferhina S. Ali, MD, MPH,⁵ Durga Borkar, MD,⁶ Theodore Leng, MD,⁷ Michael Javaheri, MD⁸ ¹Department of Ophthalmology, NYU Langone Health, New York; ²Regeneron Pharmaceuticals, Inc., Tarrytown, New York; ³Vestrum Health, Naperville, Illinois; ⁴Cleveland Clinic Martin Hospitals, Cleveland Clinic Florida, Stuart, Florida; ⁵New York Medical College, Valhalla, New York; ⁶Duke University Eye Center, Durham, North Carolina; ⁷Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California; ⁸Retina Specialists of Beverly Hills, Beverly Hills, California


BACKGROUND & PURPOSE

- In the PHOTON trial, aflibercept 8 mg achieved non-inferior visual acuity (VA) outcomes with fewer injections compared to aflibercept 2 mg in patients with diabetic macular edema (DME) through 96 weeks^{1,2}
- Real-world evidence for the use of aflibercept 8 mg in treatment-naive patients with DME could be informative for clinical practice
- This cohort study aimed to describe real-world outcomes in treatment-naive patients with DME that initiated aflibercept 8-mg treatment

METHODS

- Two cohorts of treatment-naive eyes with DME who initiated aflibercept 8 mg were identified from electronic health records in the Intelligent Research in Sight (IRIS[®]) Registry and Vestrum Health Retina database, respectively (**Figure 1**)
- Eyes initiating aflibercept 8 mg between August 18, 2023, and June 30, 2024, for the IRIS cohort, or between August 18, 2023, and July 31, 2024, for the Vestrum cohort (indexing period), were followed from initiation (index date) until last visit, treatment switch, or missing information on treatment laterality, whichever occurred first
- Data were available through December 31, 2024, for the IRIS cohort, and January 31, 2025, for the Vestrum cohort
- Injection intervals were estimated during the initial dosing phase (ie, first 3 injections or 90 days, whichever occurred first) and post-initial dosing phase
- Injection intervals were assessed in eyes with ≥ 2 injections during the initial dosing phase, and in eyes with ≥1 injection during the post-initial dosing phase
- For a subset of eyes with VA available at the index date and at 90±30 days, change in VA from treatment initiation to 90 days (VA closest to 90 days within a ±30-day window) was obtained and stratified by VA on the index date (<20/50 [<65 Early Treatment of Diabetic Retinopathy Study {ETDRS} letters] or >20/50 [>65 ETDRS letters])

Figure 1. Inclusion Criteria and Attrition



RESULTS

Table 1. Patient Characteristics on the Index Date

Mean age (SD), years

Male, n (%)

Race/ethnicity, n (%)

Hispanic or Latino

White

Black or African American

Asian or Pacific Islander

Other

Bilateral disease, n (%)

Fellow eye treated with aflibercept 8 mg on the index date, %

Mean VA (SD), ETDRS letters

NA. not available (due to limitation of the Vestrum database): SD. standard deviation

Treatment Patterns


- Mean (SD) follow-up was 138.6 (109.5) and 206.3 (111.3) days for the IRIS and Vestrum cohorts, respectively (**Table 2**)
- Mean (SD) number of injections of aflibercept 8 mg during follow-up (including the index date) was 2.5 (1.8) and 3.1 (2.1) for the IRIS and Vestrum cohorts, respectively (**Table 2**)

Table 2. Treatment Patterns During Follow-Up

	IRIS (n=1480)	Vestrum (n=633)
Duration of follow-up, days		
Mean (SD)	138.6 (109.5)	206.3 (111.3)
Median (Q1, Q3)	125 (38, 211)	207.5 (112, 291
Number of injections during follow-up		
Mean (SD)	2.5 (1.8)	3.1 (2.1)
Median (Q1, Q3)	2 (1, 3)	3 (1, 5)

- During the initial dosing phase, the mean (SD) injection interval was 41 (14) and 42 (13) days for the IRIS and Vestrum cohorts, respectively (Figure 2)
- The mean (SD) post-initial dosing phase injection interval was 77 (43) and 75 (28) days for the IRIS and Vestrum cohorts, respectively (**Figure 2**)

IRIS (n=1480)	Vestrum (n=633)
65 (11.7)	65 (11.6)
834 (56)	368 (58)
177 (14)	NA
680 (55)	NA
177 (14)	NA
46 (4)	NA
158 (13)	NA
1328 (90)	513 (81)
454 (31)	137 (22)
59.0 (23.3)	59.9 (22.2)




Visual Outcomes

Mean (SD) VA on the index date in the IRIS and Vestrum cohorts, respectively, was 45.6 (22.0) and 45.9 (21.6) letters for eyes with VA ≤20/50 on the index date, and 76.2 (5.1) and 75.3 (5.4) letters for eyes with VA >20/50 on the index date

Figure 2. Mean Injection Interval During Follow-Up

Mean change (SD) in VA at 90 days in the IRIS and Vestrum cohorts, respectively, was +8.6 (17.4) and +9.6 (19.9) letters for eyes with VA ≤20/50 on the index date, and +0.7 (6.7) and +0.4 (7.4) letters for eyes with VA >20/50 on the index date (Figure 3)

Figure 3. Mean Change in VA at 90 Days by VA on the Index Date



• The respective proportion of eyes in IRIS and Vestrum cohorts with a

Limitations

• This study was based on data from electronic medical records, which may not reflect patients' full medical history, including prior treatment history

 This study represents early real-world experience with aflibercept 8 mg and had a limited follow-up period

CONCLUSIONS

In this early real-world analysis of the IRIS and Vestrum databases of treatment-naive patients with DME, eyes with VA ≤20/50 on the index date achieved clinically meaningful improvements in vision with aflibercept 8 mg at the end of the initial dosing phase

- Mean VA remained stable in eyes with good baseline vision (VA >20/50 on the index date), likely due to the ceiling effect minimizing potential improvement
- On average, patients with treatment-naive DME achieved injection intervals of ~75 days (~11 weeks) with aflibercept 8 mg
- Additional analyses with longer follow-up periods are ongoing to assess the long-term effect of aflibercept 8 mg on durability and outcomes in patients with treatment-naive DME in the real world

REFERENCES

. Brown DM et al. Lancet. 2024;403:1153-1163.

2. Do D. Presented at the American Academy of Ophthalmology Meeting; November 3-6, 2023; San Francisco, CA.

ACKNOWLEDGMENTS & DISCLOSURES

Nitish Mehta has no disclosures to report. Steven Sherman, Dana Murdock, and Keran Moll are employees and stockholders of Regenero

Pharmaceuticals, Inc. Nick Boucher is an employee of Vestrum Health. Rishi P. Singh reports personal fees from Apellis, Iveric Bio, EvePoint. REGENXBIO, Genentech, Bausch + Lomb, Zeiss, Alcon, and Regeneron Pharmaceuticals, Inc., and research grants from Janssen. Ferhina S. Ali has received honoraria and served on speaker bureaus for 4DMT, Allergan, Apellis, EyePoint, Genentech, Iveric Bio, OcuTerra, Optomed, Ocuphire, Outlook Therapeutics, and Regeneron Pharmaceuticals, Inc. Durga Borkar has acted as a consultant for 4DMT, Alimera Sciences, Astellas, Apellis AbbVie/Allergan, EyePoint, Genentech, Glaukos, ONL Therapeutics, Regeneron Pharmaceuticals, Inc., and Verana Health; and has served as a speaker for Astellas and Genentech. Theodore Leng reports funding from Astellas and acted as a consultant for Astellas, Boehringer Ingelheim, Regeneron Pharmaceuticals, Inc., Roche/Genentech, Topcon, and Virtual Field. Michael Javaheri has acted as a speaker and consultant and partaken in advisory boards with Genentech and Regeneron Pharmaceuticals, Inc.

This analysis was funded by Regeneron Pharmaceuticals, Inc. (Tarrytown, New York). The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this poster

Medical writing support was provided by Matthew Young, DPhil, and editorial support by Jess Fawcett, BSc, of Core (a division of Prime, London, UK), funded by Regeneron Pharmaceuticals, Inc. according to Good Publication Practice guidelines